Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
New York Composite
Gold
Crude Oil
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries
Sanofi-Aventis S.A.
(NY:
SNY
)
43.41
USD
UNCHANGED
Last Price
Updated: 5:16 PM EST, Dec 31, 2018
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press releases about Sanofi-Aventis S.A.
< Previous
1
2
3
4
5
6
7
8
9
...
58
59
Next >
Biond Biologics and Sanofi Enter into Global Licensing Agreement for BND-22, a Novel Immune Checkpoint Inhibitor Targeting the ILT2 Receptor
January 12, 2021
Biond to receive $125 million upfront with more than $1 billion in potential development, regulatory, and sales milestones plus royalty payments
From
PR Newswire
Moderna Provides Business Update and Announces Three New Development Programs in Infectious Disease Vaccines
January 11, 2021
Moderna Provides Business Update and Announces Three New Development Programs in Infectious Disease Vaccines
From
Business Wire News Releases
Corinne Le Goff, Pharm.D. Will Join Moderna as Chief Commercial Officer on January 19
January 07, 2021
Corinne Le Goff, Pharm.D. will join Moderna as Chief Commercial Officer on January 19.
From
Business Wire News Releases
Canadians living with multiple sclerosis find support during COVID-19 pandemic through dedicated social media network
December 08, 2020
From
PR Newswire
Anti-Fibrinolytic Drugs Market Size, Share, Price, Trends, Growth, Analysis, Key Players, Outlook, Report, Forecast 2021-2026 | ExpertMarketResearch.com
December 07, 2020
Tags
iCN Internal Distribution
English
Extended Distribution
From
iCrowdNewswire
Sanofi and the Parkinson's Foundation collaborate to advance the availability of free genetic testing and counseling for people with Parkinson's disease
October 21, 2020
* $1 million in research funding to support PD GENEration, a first-of-its-kind national study offering free genetic testing and counseling for people with Parkinson's disease (PD)
From
PR Newswire
EmergingGrowth.com Reports on Why Galectin Therapeutics is Due for a COVID-19 Makeover
September 29, 2020
Tags
IPS
Extended Distribution
English
From
iCrowdNewswire
EmergingGrowth.com Reports on Why Galectin Therapeutics (GALT) is Due for a COVID-19 Makeover
September 29, 2020
Tags
banking/finance/investment
c:canada
business/economy
From
EIN Presswire
(PRNB) Alert: Johnson Fistel Investigates Proposed Sale of Principia Biopharma; Is $100 a Fair Price?
September 12, 2020
Shareholder rights law firm Johnson Fistel, LLP has launched an investigation into whether the board members of Principia Biopharma Inc. ("Principia " or the "Company") (NASDAQ: PRNB) breached their...
From
PR Newswire
Sanofi Genzyme continues research to improve the lives of patients with multiple sclerosis, with new data presented at MSVirtual2020
September 09, 2020
- New data on investigational brain-penetrant BTK inhibitor tolebrutinib (SAR442168) further support its potential in modulating disabling inflammatory processes within the central nervous system
From
PR Newswire
Biopharma Leaders Unite to Stand With Science
September 08, 2020
The CEOs of AstraZeneca (LSE/STO/NYSE: AZN), BioNTech (NASDAQ: BNTX), GlaxoSmithKline plc (LSE/NYSE: GSK), Johnson & Johnson (NYSE: JNJ), Merck (NYSE: MRK), known as MSD outside the United States and...
From
Business Wire News Releases
Biopharma Leaders Unite to Stand with Science
September 08, 2020
From
GlobeNewswire News Releases
Biopharma Leaders Unite to Stand with Science
September 08, 2020
The CEOs of AstraZeneca (LSE/STO/NYSE: AZN), BioNTech (NASDAQ: BNTX), GlaxoSmithKline plc (LSE/NYSE: GSK), Johnson & Johnson (NYSE: JNJ), Merck (NYSE: MRK), known as MSD outside the United States and...
From
Business Wire News Releases
Biopharma Leaders Unite To Stand With Science
September 08, 2020
Biopharma leaders unite to stand with science.
From
Business Wire News Releases
(PRNB) Alert: Johnson Fistel Investigates Proposed Sale of Principia Biopharma; Are Shareholders Getting a Fair Price?
August 18, 2020
From
GlobeNewswire News Releases
PRINCIPIA ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of PRNB and Encourages Investors to Contact the Firm
August 17, 2020
Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the board members of Principia Biopharma Inc. (NASDAQ: PRNB) breached their...
From
Business Wire News Releases
PRINCIPIA BIOPHARMA INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation of Buyout
August 17, 2020
From
GlobeNewswire News Releases
(PRNB) Alert: Johnson Fistel Investigates Proposed Sale of Principia Biopharma; Is $100 a Fair Price?
August 17, 2020
Shareholder rights law firm Johnson Fistel, LLP has launched an investigation into whether the board members of Principia Biopharma Inc. ("Principia " or the "Company") (NASDAQ: PRNB) breached their...
From
PR Newswire
Sanofi to acquire Principia Biopharma
August 17, 2020
* Further strengthens core R&D areas of autoimmune and allergic diseases
From
PR Newswire
Sanofi H1 2020 business EPS(1) growth of 9.2%(2) driven by transformation
July 29, 2020
Sanofi (NASDAQ: SNY; EURONEXT: SAN)
From
PR Newswire
AllPennyStocks.com News: Plant-Based Biopharma Company Jumps to Six-Month High on Clinical Trials for Depression, ADHD
July 28, 2020
From
SBWire - Latest Press Releases
Sanofi and MD Anderson announce strategic collaboration to accelerate oncology research and development
July 14, 2020
* New alliance will use insights from translational and clinical studies to better identify targets, combinations and potential new indications for current medicines
From
PR Newswire
Kymera Therapeutics And Sanofi Enter Into Strategic Partnership To Advance Novel Protein Degrader Therapies To Patients
July 09, 2020
- Kymera to receive $150 million upfront with more than $2 billion in potential milestones plus royalty payments -
From
PR Newswire
FDA approves new Dupixent® (dupilumab) pre-filled pen designed to support more convenient self-administration
June 19, 2020
* Single-dose (300 mg) pre-filled pen provides additional administration option to adults and adolescents who are prescribed Dupixent
From
PR Newswire
Sanofi's emerging oncology pipeline highlighted at the AACR Virtual Annual Meeting II
June 15, 2020
- Preclinical data show anti-tumor activity in Sanofi's investigational compounds, including an oral selective estrogen receptor degrader (SERD) and an anti-CEACAM5 antibody-drug conjugate
From
PR Newswire
Sanofi and Sobi donate up to 500 million additional IUs of clotting factor to WFH Humanitarian Aid Program
June 14, 2020
* Additional donation of factor therapy fulfills 2014 pledge to donate up to an unprecedented 1 billion IUs for humanitarian use
From
PR Newswire
Regeneron Announces Secondary Offering of its Common Stock Held by Sanofi and $5 Billion Stock Repurchase
May 25, 2020
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the commencement of an underwritten public secondary offering of its common stock through which Sanofi (NASDAQ: SNY) intends to exit its...
From
PR Newswire
Sanofi to showcase oncology portfolio and innovative pipeline at ASCO20 Virtual Scientific Program
May 13, 2020
- Emerging data demonstrate commitment to advancing cancer care, including two fully in-house investigational compounds: a potential best-in-class oral SERD for breast cancer and a first-in-class...
From
PR Newswire
NASDAQ:SNY Shareholder Notice: Investigation over Possible Violations of Securities Laws by Sanofi
May 06, 2020
San Diego, CA -- (SBWIRE) -- 05/06/2020 -- Sanofi is under investigation over potential securities laws violations by Sanofi in connection with certain financial statements.
From
SBWire - Latest Press Releases
Sanofi at forefront of fight against COVID-19 in Q1 2020
April 24, 2020
Sanofi (NASDAQ: SNY; EURONEXT: SAN)
From
PR Newswire
< Previous
1
2
3
4
5
6
7
8
9
...
58
59
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.